Medical professionals are shifting toward pulsed field ablation as a safer alternative to traditional thermal methods for treating heart rhythm disorders.
This transition is significant because traditional ablation relies on extreme heat or cold, which can inadvertently damage surrounding healthy tissue. Pulsed field ablation uses electrical pulses to create microscopic pores in cell membranes, allowing for a more targeted approach that preserves adjacent structures.
Dr. Christopher DeSimone and Dr. Anthony Kashou said the mechanisms and clinical advantages of the technology in a recent Mayo Clinic presentation. The technology first received approval in the U.S. in early 2024 [3].
Clinical data suggests that the newer method is as effective as older techniques. Researchers said that atrial fibrillation recurrence after pulsed field ablation was comparable to radiofrequency ablation [1]. However, trial investigators said that pulsed field ablation did not have superior efficacy to radiofrequency ablation in patients with drug-resistant paroxysmal atrial fibrillation [4].
Despite the lack of superior efficacy in some cases, the safety profile remains a primary driver for adoption. Data indicates there are fewer procedure-related adverse events with pulsed field ablation compared to thermal methods [5].
The industry is investing heavily to scale these capabilities. The CEO of Kardium said the company raised $250 million to expand its Globe system and bring pulsed field ablation to more patients [2].
This shift represents a broader move in cardiology toward non-thermal energy sources. By avoiding the risks associated with heat-induced scarring, clinicians can potentially reduce complications during complex heart procedures.
“AF recurrence after pulsed field ablation was comparable to radiofrequency ablation.”
The adoption of pulsed field ablation marks a pivot from 'thermal' to 'non-thermal' cardiac care. While it may not consistently outperform radiofrequency ablation in terms of curing atrial fibrillation, its primary value lies in risk mitigation. By reducing collateral tissue damage, the technology lowers the threshold for patient safety and potentially expands the number of candidates eligible for ablation therapy.
